We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Osteopontin Biomarker Evaluated for COVID-19 Severity and MIS-C

By LabMedica International staff writers
Posted on 27 Oct 2021
Print article
Image: Osteopontin is a biomarker for multisystem inflammatory syndrome in children (MIS-C) (Photo courtesy of Getty Images)
Image: Osteopontin is a biomarker for multisystem inflammatory syndrome in children (MIS-C) (Photo courtesy of Getty Images)
Multisystem inflammatory syndrome in children (MIS-C) is a serious condition that appears to be linked to coronavirus disease 2019 (COVID-19). Most children who become infected with the COVID-19 virus have only a mild illness.

Osteopontin (OPN) is a highly phosphorylated glycophosphoprotein having acidic characteristics and rich in aspartic acid. OPN, a multifunctional protein, has important functions on cardiovascular diseases, cancer, diabetes and kidney stone diseases and in the process of inflammation, biomineralization, cell viability and wound healing.

Pediatricians at the Emory University School of Medicine (Atlanta, GA, USA) and their colleagues evaluated the candidacy of plasma osteopontin (OPN) as a biomarker of COVID-19 severity and multisystem inflammatory condition in children (MIS-C) in children. They conducted a retrospective analysis of 26 children (0–21 years of age) admitted to Children’s Healthcare of Atlanta (Atlanta, GA, USA) with a diagnosis of COVID-19 between March 17 and May 26, 2020.

The patients were classified into three categories based on COVID-19 severity levels: asymptomatic or minimally symptomatic (control population, admitted for other non-COVID-19 conditions), mild/moderate, and severe COVID-19. A fourth category of children met the Centers for Disease Control and Prevention's case definition for MIS-C. Residual blood samples were analyzed for OPN, a marker of inflammation using commercial ELISA kits (R&D Systems, Minneapolis, MN, USA), and results were correlated with clinical data.

The investigators reported that plasma osteopontin levels significantly differed across the groups. Osteopontin was significantly elevated in patients with moderate or severe COVID-19 and MIS-C, at a median of 430.32 ng/mL and 598.11 ng/mL, respectively, compared with those in the mild or asymptomatic groups. In addition, osteopontin differentiated among levels of severity in COVID-19, while other inflammatory markers, including maximum erythrocyte sedimentation rate, C-reactive protein and ferritin, minimum lymphocyte and platelet counts, soluble interleukin-2R, and interleukin-6, did not.

Andrew Reisner, MD, a Neurosurgeon and first author of the study, said, “This study demonstrated that osteopontin is significantly upregulated in the plasma of hospitalized children with SARS-CoV-2 infection and MIS-C versus mild or asymptomatic children. Further, osteopontin levels correlated with clinical severity of COVID-19, also with statistical significance. These new data suggest that osteopontin is a putative biomarker to guide risk stratification, prognostication, and clinical management of children with COVID-19 and MIS-C.”

The authors concluded that OPN is a potential biomarker of COVID-19 severity and MIS-C in children that may have future clinical utility. The specificity and positive predictive value of this marker for COVID-19 and MIS-C are areas for future larger prospective studies. The study was published on September 26, 2021 in the journal Experimental Biology and Medicine.

Related Links:
Emory University School of Medicine
Children’s Healthcare of Atlanta
R&D Systems


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.